GO Term |
---|
response to glucocorticoid |
response to calcium ion |
striated muscle cell development |
Sertoli cell development |
GO Term |
---|
extracellular exosome |
Golgi lumen |
external side of plasma membrane |
cell surface |
lysosomal lumen |
plasma membrane |
protein-containing complex |
GO Term |
---|
cargo receptor activity |
identical protein binding |
Position | Description | PubMed ID | GlyTouCan ID | Source |
---|---|---|---|---|
37 | O-linked (Xyl...) (chondroitin sulfate) serine |
|
||
43 | N-linked (GlcNAc...) asparagine |
|
||
45 | O-linked (Xyl...) (heparan sulfate) serine |
|
||
47 | O-linked (Xyl...) (heparan sulfate) serine |
|
||
58 |
|
|||
61 |
|
|||
63 |
|
|||
64 |
|
|||
72 |
|
|||
76 |
|
Pathway Name | Organism |
---|---|
A tetrasaccharide linker sequence is required for GAG synthesis | Homo sapiens |
Attachment and Entry | Homo sapiens |
Cell surface interactions at the vascular wall | Homo sapiens |
Defective B3GALT6 causes EDSP2 and SEMDJL1 | Homo sapiens |
Defective B3GAT3 causes JDSSDHD | Homo sapiens |
Defective B4GALT7 causes EDS, progeroid type | Homo sapiens |
Defective EXT1 causes exostoses 1, TRPS2 and CHDS | Homo sapiens |
Defective EXT2 causes exostoses 2 | Homo sapiens |
HS-GAG biosynthesis | Homo sapiens |
HS-GAG degradation | Homo sapiens |
Tissue with high expression from Human Protein Atlas. Tissues that are highly expressed are highlighted.
DO ID | Disease Name | Source |
---|---|---|
DOID:10286 | prostate carcinoma | |
DOID:104 | bacterial infectious disease | |
DOID:1040 | chronic lymphocytic leukemia | |
DOID:10534 | stomach cancer | |
DOID:10591 | pre-eclampsia | |
DOID:10608 | celiac disease | |
DOID:10629 | microphthalmia | |
DOID:1063 | interstitial nephritis | |
DOID:1074 | kidney failure | |
DOID:10763 | hypertension |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
GlyCosmos Portal v4.0.0
Last updated: August 19, 2024